Jinyu Bio-Technology subsidiary obtains new veterinary drug certificate for cattle vaccine

Jinyu Baoling Biological Products Co., Ltd., in collaboration with other companies, has successfully developed a gene-engineered subunit vaccine for Clostridium perfringens type A in cattle. The National Agricultural and Rural Affairs Department approved the vaccine as a new veterinary drug, issuing certificate number (2025) New Veterinary Drug Certificate No. 116. This Class II new veterinary drug contains inactivated bovine type A Clostridium perfringens alpha toxin protein, with each dose containing 200μg of alpha toxin protein.

The vaccine is designed to prevent sudden death in cattle caused by Clostridium perfringens type A, providing five months of immunity seven days after the second vaccination. It is administered intramuscularly to cattle aged one month and above, with a dose of 2.0ml, followed by a booster 21 days later. Subsequent vaccinations are recommended every five months. The product has a shelf life of 18 months when stored at 2-8℃.

This achievement significantly bolsters Jinyu Bio-Technology's ruminant vaccine product portfolio, reinforcing its leading position in the field. The successful approval of this gene-engineered subunit vaccine also demonstrates the company's enhanced maturity in gene engineering subunit vaccine technology, positively impacting its R&D capabilities, market competitiveness, and sustainable development.